Fate Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US31189P1021
USD
1.22
0.07 (6.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
CorMedix, Inc.
Xeris Biopharma Holdings, Inc.
Poseida Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Lineage Cell Therapeutics, Inc.
Verastem, Inc.
Fate Therapeutics, Inc.
Akoya Biosciences, Inc.
AlloVir, Inc.
Reneo Pharmaceuticals, Inc.
Synlogic, Inc.

Why is Fate Therapeutics, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate -6.69% of over the last 5 years
2
Flat results in Sep 25
  • NET SALES(Q) At USD 1.74 MM has Fallen at -17.78%
  • ROCE(HY) Lowest at -52.35%
  • RAW MATERIAL COST(Y) Grown by 69.75% (YoY)
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 20.11%, its profits have risen by 20%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Fate Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Fate Therapeutics, Inc.
29.68%
-0.73
97.29%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-17.19%
EBIT Growth (5y)
-6.69%
EBIT to Interest (avg)
-209.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
0.47
EV to EBITDA
0.52
EV to Capital Employed
-3.24
EV to Sales
-10.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-60.73%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -110.57 MM

OPERATING PROFIT(Q)

Highest at USD -31.51 MM

PRE-TAX PROFIT(Q)

Highest at USD -32.16 MM

NET PROFIT(Q)

Highest at USD -32.16 MM

EPS(Q)

Highest at USD -0.27

-15What is not working for the Company
NET SALES(Q)

At USD 1.74 MM has Fallen at -17.78%

ROCE(HY)

Lowest at -52.35%

RAW MATERIAL COST(Y)

Grown by 69.75% (YoY

CASH AND EQV(HY)

Lowest at USD 438.25 MM

Here's what is working for Fate Therapeutics, Inc.

Operating Cash Flow
Highest at USD -110.57 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit
Highest at USD -31.51 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -32.16 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -32.16 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

EPS
Highest at USD -0.27
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Fate Therapeutics, Inc.

Net Sales
At USD 1.74 MM has Fallen at -17.78%
over average net sales of the previous four periods of USD 2.12 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Cash and Eqv
Lowest at USD 438.25 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost
Grown by 69.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales